Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Tagawa, S. T. [1 ]
Sun, M. [2 ]
Sartor, O. [3 ]
Thomas, C. [4 ]
Molina, A. M. [1 ]
Sternberg, C. N. [5 ]
Nanus, D. M. [6 ]
Osborne, J. [7 ]
Bander, N. [8 ]
机构：
[1] Weill Cornell Med Ctr, Urol, Hematol & Med Oncol, New York, NY USA
[2] Weill Cornell Med Ctr, Hematol & Med Oncol, New York, NY USA
[3] Tulane Med Sch, Med Sch, New Orleans, AL USA
[4] Weill Cornell Med Ctr, Biostat, New York, NY USA
[5] Cornell Univ, Weill Cornell Med Coll, Dept Hematol & Oncol, New York, NY USA
[6] Weill Cornell Med Coll, Med, New York, NY USA
[7] Weill Cornell Med Ctr, Radiol, New York, NY USA
[8] Weill Cornell Med Ctr, Urol, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600P
引用
收藏
页码：S645 / S645
页数：1
相关论文
共 50 条
  • [21] LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Kostos, Louise Kathleen
    Buteau, James Patrick
    Kong, Grace
    Yeung, Theresa
    Di Iulio, Juliana
    Fahey, Michael T.
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney
    Norouzi, Ghazal
    Aghdam, Ramin Akbarian
    Hashemifard, Hamidreza
    Pirayesh, Elahe
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 483 - 484
  • [23] Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
    Emmett, L.
    Subramaniam, S.
    Crumbaker, M.
    Joshua, A. M.
    Weickhardt, A. J.
    Lee, S. T.
    Ng, S.
    Francis, R. J.
    Goh, J. C. H.
    Pattison, D. A.
    Tan, H.
    Kirkwood, I. D.
    Sandhu, S. K.
    Nguyen, A.
    Gedye, C.
    Rutherford, N.
    Hofman, M.
    Martin, A.
    Stockler, M. R.
    Davis, I. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1325 - S1325
  • [24] Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Aggarwal, Piyush
    Gunasekaran, Vinisha
    Sood, Ashwani
    Kumar, Narendra
    Rathore, Yogesh
    Kumar, Rajender
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (03) : 231 - 233
  • [25] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [26] Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.
    De Giorgi, Ugo
    Severi, Stefano
    Sarnelli, Anna
    Sansovini, Maddalena
    Monti, Manuela
    Gurioli, Giorgia
    Nicolini, Silvia
    Scarpi, Emanuela
    Casadei, Chiara
    Conteduca, Vincenza
    Matteucci, Federica
    Di Iorio, Valentina
    Amadori, Dino
    Paganelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [28] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [29] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.
    Herrmann, Ken
    Rahbar, Kambiz
    Eiber, Matthias
    Krause, Bernd J.
    Lassmann, Michael
    Jentzen, Walter
    Blumenstein, Lars
    Klein, Patrick
    Basque, Jean-Rene
    Kurth, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [30] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
12345